Author:
Lee Byung,Mukhi Nikhil,Liu Delong
Abstract
Abstract
Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology
Reference41 articles.
1. DeVita VT, Lawrence TS, Rosenberg SA: DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 2008, Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 8
2. Eggermont AM: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008, 372 (9633): 117-26. 10.1016/S0140-6736(08)61033-8.
3. Chapman PB: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364 (26): 2507-16. 10.1056/NEJMoa1103782.
4. Hodi FS: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363 (8): 711-23. 10.1056/NEJMoa1003466.
5. Jemal A: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献